Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;63(9):768-779.
doi: 10.1007/s12033-021-00345-4. Epub 2021 May 31.

CRISPR-Based Genome Editing as a New Therapeutic Tool in Retinal Diseases

Seyed Ahmad Rasoulinejad  1 , Faezeh Maroufi  2
Affiliations
Review

CRISPR-Based Genome Editing as a New Therapeutic Tool in Retinal Diseases

Seyed Ahmad Rasoulinejad et al. Mol Biotechnol. 2021 Sep.

Abstract

Retinal diseases are the primary reasons for severe visual defects and irreversible blindness. Retinal diseases are also inherited and acquired. Both of them are caused by mutations in genes or disruptions in specific gene expression, which can be treated by gene-editing therapy. Clustered regularly interspaced short palindromic repeats (CRISPR-Cas9) system is a frontier of gene-editing tools with great potential for therapeutic applications in the ophthalmology field to modify abnormal genes and treat the genome or epigenome-related retinal diseases. The CRISPR system is able to edit and trim the gene include deletion, insertion, inhibition, activation, replacing, remodeling, epigenetic alteration, and modify the gene expression. CRISPR-based genome editing techniques have indicated the enormous potential to treat retinal diseases that previous treatment was not available for them. Also, recent CRISPR genome surgery experiments have shown the improvement of patient's vision who suffered from severe visual loss. In this article, we review the applications of the CRISPR-Cas9 system in human or animal models for treating retinal diseases such as retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), age-related macular degeneration (AMD), proliferative diabetic retinopathy (PDR), and proliferative vitreoretinopathy (PVR), then we survey limitations of CRISPR system for clinical therapy.

Keywords: CRISPR-Cas9; Gene knock-out; Genome editing; Retinal diseases.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Yuzawa, M., Fujita, K., Tanaka, E., & Wang, E. C. (2013). Assessing quality of life in the treatment of patients with age-related macular degeneration: Clinical research findings and recommendations for clinical practice. Clinical Ophthalmology., 7, 1325–1332. - PubMed - PMC - DOI
    1. Hung, S. S. C., McCaughey, T., Swann, O., Pebay, A., & Hewitt, A. W. (2016). Genome engineering in ophthalmology: Application of CRISPR/Cas to the treatment of eye disease. Progress in Retinal and Eye Research., 53, 1–20. - PubMed - DOI
    1. Smith, J., Ward, D., Michaelides, M., Moore, A. T., & Simpson, S. (2015). New and emerging technologies for the treatment of inherited retinal diseases: A horizon scanning review. Eye, 29(9), 1131–1140. - PubMed - PMC - DOI
    1. Rasoulinejad, S. A., Kasiri, A., Montazeri, M., Rashidi, N., Montazeri, M., Montazeri, M., et al. (2015). The association between primary open angle glaucoma and clustered components of metabolic syndrome. Open Ophthalmology Journal, 9, 149–155. - DOI
    1. Maali, A., Atashi, A., Ghaffari, S., Kouchaki, R., Abdolmaleki, F., & Azad, M. (2018). A review on leukemia and iPSC technology: Application in novel treatment and future. Current Stem Cell Research & Therapy, 13(8), 665–675. - DOI

MeSH terms

Substances